Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $8.5300 (26.56%) ($6.6700 - $8.5800) on Tue. Mar. 17, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.95% (three month average) | RSI | 48 | Latest Price | $8.5300(26.56%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -10% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) IWO(55%) XBI(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -3.475% in a week (0% probabilities). VIXM(-33%) VXX(-18%) TLT(-13%) IGOV(-6%) UNG(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.475% (StdDev 6.95%) | Hourly BBV | 0 () | Intraday Trend | 23.4% | | | |
|
1 - 5 Day Possible Target | $-15.02(-276.08%) | Resistance Level | $9.16 | 5 Day Moving Average | $7.64(11.65%) | 10 Day Moving Average | $8.41(1.43%) | 20 Day Moving Average | $9.16(-6.88%) | To recent high | -23.6% | To recent low | 28.7% | Market Cap | $2.203b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |